Source link : https://www.newshealth.biz/health-news/genetic-testing-low-in-castration-resistant-prostate-cancer/
TOPLINE: A minority of patients with metastatic castration-resistant prostate cancer (mCRPC) in the United States undergo genetic testing for homologous recombination repair (HRR) mutations, despite the potential prognostic and predictive value of these mutations for therapies like poly(ADP-ribose) polymerase (PARP) inhibitors, research shows. METHODOLOGY: HRR gene mutations are found in approximately 25%-30% of patients with […]
Author : News Health
Publish date : 2024-05-17 10:00:19
Copyright for syndicated content belongs to the linked Source.